DK1754713T3 - Peptider, der binder sig til Apo2L (Trail)-receptorer samt anvendelser deraf - Google Patents

Peptider, der binder sig til Apo2L (Trail)-receptorer samt anvendelser deraf

Info

Publication number
DK1754713T3
DK1754713T3 DK06013626T DK06013626T DK1754713T3 DK 1754713 T3 DK1754713 T3 DK 1754713T3 DK 06013626 T DK06013626 T DK 06013626T DK 06013626 T DK06013626 T DK 06013626T DK 1754713 T3 DK1754713 T3 DK 1754713T3
Authority
DK
Denmark
Prior art keywords
peptides
bind
apo2l
trail
receptors
Prior art date
Application number
DK06013626T
Other languages
English (en)
Inventor
Bing Li
Sachdev S Sidhu
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of DK1754713T3 publication Critical patent/DK1754713T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK06013626T 2003-05-09 2004-04-29 Peptider, der binder sig til Apo2L (Trail)-receptorer samt anvendelser deraf DK1754713T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46943603P 2003-05-09 2003-05-09
PCT/US2004/013576 WO2004101608A2 (en) 2003-05-09 2004-04-29 Apo2l (trail) receptor binding peptides and uses thereof

Publications (1)

Publication Number Publication Date
DK1754713T3 true DK1754713T3 (da) 2009-06-08

Family

ID=33452286

Family Applications (2)

Application Number Title Priority Date Filing Date
DK06013626T DK1754713T3 (da) 2003-05-09 2004-04-29 Peptider, der binder sig til Apo2L (Trail)-receptorer samt anvendelser deraf
DK04760861T DK1622929T3 (da) 2003-05-09 2004-04-29 Apo-2L (TRAIL) receptorbindingspeptider og anvendelser deraf

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK04760861T DK1622929T3 (da) 2003-05-09 2004-04-29 Apo-2L (TRAIL) receptorbindingspeptider og anvendelser deraf

Country Status (12)

Country Link
US (1) US20070066800A1 (da)
EP (2) EP1622929B1 (da)
JP (1) JP2007530008A (da)
AT (2) ATE342274T1 (da)
AU (1) AU2004238794A1 (da)
CA (1) CA2524456A1 (da)
DE (2) DE602004019701D1 (da)
DK (2) DK1754713T3 (da)
ES (2) ES2274480T3 (da)
IL (1) IL171733A (da)
PL (2) PL1754713T3 (da)
WO (1) WO2004101608A2 (da)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0509201A (pt) 2004-03-23 2007-08-28 Biogen Idec Inc agentes de acoplamento de receptor e usos terapêuticos destes
US20060188498A1 (en) * 2005-02-18 2006-08-24 Genentech, Inc. Methods of using death receptor agonists and EGFR inhibitors
US20090131317A1 (en) * 2007-06-22 2009-05-21 Affymax, Inc. Compounds and peptides that bind the trail receptor
CA2749512A1 (en) * 2009-04-03 2010-10-07 Institute Of Basic Medical Sciences, Chinese Academy Of Medical Sciences Antigenic determinants recognized by anti-human death receptor dr5 monoclonal antibody ad5-10, derivatives and use thereof
JP2013507124A (ja) * 2009-10-09 2013-03-04 アナフォア インコーポレイテッド Ｉｌ−２３ｒを結合するポリペプチド
US11299528B2 (en) 2014-03-11 2022-04-12 D&D Pharmatech Inc. Long acting TRAIL receptor agonists for treatment of autoimmune diseases
FR3031112B1 (fr) * 2014-12-24 2018-05-25 Eyevensys Construction d'adn pour le traitement de pathologies oculaires
CN105061604B (zh) * 2015-08-19 2018-03-16 河南大学 sDR5‑Fc融合蛋白突变体及其应用
US11007251B2 (en) 2015-12-17 2021-05-18 The Johns Hopkins University Ameliorating systemic sclerosis with death receptor agonists
AU2017248264B2 (en) 2016-04-07 2020-01-30 The Johns Hopkins University Compositions and methods for treating pancreatitis and pain with death receptor agonists
CN116585484B (zh) * 2022-12-13 2023-12-12 广州医科大学 多肽偶联小分子化合物及其抗病毒应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6252050B1 (en) * 1998-06-12 2001-06-26 Genentech, Inc. Method for making monoclonal antibodies and cross-reactive antibodies obtainable by the method

Also Published As

Publication number Publication date
EP1754713A1 (en) 2007-02-21
AU2004238794A1 (en) 2004-11-25
CA2524456A1 (en) 2004-11-25
WO2004101608A3 (en) 2004-12-29
ES2322182T3 (es) 2009-06-17
ATE342274T1 (de) 2006-11-15
DE602004002773D1 (de) 2006-11-23
DE602004002773T2 (de) 2007-08-16
PL1622929T3 (pl) 2007-03-30
DE602004019701D1 (de) 2009-04-09
WO2004101608A2 (en) 2004-11-25
DK1622929T3 (da) 2007-02-19
ATE423786T1 (de) 2009-03-15
IL171733A (en) 2010-11-30
EP1622929A2 (en) 2006-02-08
EP1754713B1 (en) 2009-02-25
JP2007530008A (ja) 2007-11-01
EP1622929B1 (en) 2006-10-11
ES2274480T3 (es) 2007-05-16
PL1754713T3 (pl) 2009-07-31
US20070066800A1 (en) 2007-03-22

Similar Documents

Publication Publication Date Title
DE60234202D1 (de) Taci-immunoglobulin-fusionsproteine
DE60325892D1 (de) Stellungs- und verwendungsverfahren
ATE309347T1 (de) Protocadherin-proteine und verwendungen davon
DK1450847T3 (da) Apo2-ligand/TRAIL-formuleringer og anvendelser deraf
WO2005100399A3 (en) Dr5 antibodies and uses thereof
DK1536778T3 (da) Proteiner, der binder til cross-beta-strukturholdigt amyloid og fremgangsmåder til modulation af cross-beta-strukturen, dens dannelse og dens associerede toksicitet
ATE517120T1 (de) Igf-1 fusion polypeptide und deren therapeutische verwendung
DK1622929T3 (da) Apo-2L (TRAIL) receptorbindingspeptider og anvendelser deraf
EA200800301A1 (ru) Протеины, связывающие il-6
CY1109904T1 (el) Προαγωγεας της il-18bp, η παρασκευη και χρηση του
FI20040813L (fi) Hydrofobisia molekyylejä stabiloivat proteiinit
Marx NANOTECH'S FIRST LINE OF DEFENSE